Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Meta-cognitive Therapy (MCT) versus Cognitive Behaviour Therapy (CBT) for Depression
ISRCTN ISRCTN82799488
DOI 10.1186/ISRCTN82799488
ClinicalTrials.gov identifier
EudraCT number
Public title Meta-cognitive Therapy (MCT) versus Cognitive Behaviour Therapy (CBT) for Depression
Scientific title Meta-cognitive Therapy (MCT) versus Cognitive Behaviour Therapy (CBT) for Depression: A randomised clinical trial
Acronym MetaDep
Serial number at source N/A
Study hypothesis The null hypothesis is that MCT is just as effective as CBT.
Lay summary Background and study aims
Depression is considered the second leading cause of disability caused by illness affecting about 121 million people around the world. Cognitive behaviour therapy (CBT) is an evidence-based treatment for depression. However, only approximately 5 out of 10 of patients respond and only a third remain recovered at follow-up. Initial studies show that meta-cognitive therapy (MCT) might optimize effectiveness. The present study intents to compare 128 depressed Danish outpatients randomly assigned to up to 24 weekly sessions of either CBT or MCT. The approach of the data-analysis consists of a mixed-model analysis of variance and analysis of co-variance to assess relative treatment effects. The results of the trial will have significant impact on enhancing treatment methods for depression.

Who can participate?
Participants are patients referred from their general practitioner (GP) to get psychological treatment at the CEKTOS center for their depression who want treatment within 2 weeks and are willing to participate in a trial.

What does the study involve?
After screening and diagnosis the participants are randomly allocated to receive either treatment as usual - CBT or MCT.
Patients who are suitable for the trial receive either up to 24 sessions of CBT or MCT.

What are the possible benefits and risks of participating?
No known risks or side effects from either CBT or MCT.

Where is the study run from?
It takes place at CEKTOS Center for Kognitiv Terapi og Supervision in Næstved. Supervision is given at Manchester University where the manager of the trial is a PhD student.

When is the study starting and how long is it expected to run for?
The trial started in 2010 and is expected to run for at least 4 years.

Who is funding the study?
It is a privately funded study sponsored by CEKTOS- Center for Kognitiv Terapi og Supervision.

Who is the main contact?
Pia Callesen
pcallesen@gmail.com
Pia.callesen@cektos.dk
Ethics approval Danish Ethical Committee, 13 December 2010
Study design Randomised parallel between-groups design. Groups are stratified for gender and level of depression.
Countries of recruitment Denmark
Disease/condition/study domain Depression
Participants - inclusion criteria 1. Patients (male and female, aged 18-68 years) who have a main or primary diagnosis of major depressive disorder (MDD) according to Structured Clinical Interview for DSM-IV Disorders (SCID) I.
2. Patients who only attend therapy in this trial and have not received other psychological treatments for the current episode.
3. Patients in combined medical treatment as long as they are stable or willing to remain stable on their medication for the period of the trial.
4. Patients who sign informed consent
Participants - exclusion criteria 1. Patients suffering from psychosis or bipolar disorder as screened by SCID I
2. Patients suffering from substance and alcohol-abuse as screened by SCID I
3. Patients suffering from borderline personality disorder as screened by SCID II
4. Patients with organic brain syndrome or mental retardation
5. Female patients who are pregnant or lactating
6. Participants who had not responded favorably to an earlier adequate trial of either CBT or MCT
Anticipated start date 01/11/2010
Anticipated end date 01/11/2015
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 128
Interventions Cognitive behaviour therapy versus metacognitive behaviour therapy.

The two therapists in the trial give both treatment. Patients are referred according to therapist availability. They are offered up to 24 sessions of 50-60 mins. once a week. Treatment is terminated when they score below depressive threshold on the BDI-II in two consecutive sessions. Patients symptoms are evaluated before, mid, post and at 6 months follow-up.
Primary outcome measure(s) 1. Depressive symptoms (Hamilton Depression Inventory administered by blind assessor)
2. Depressive symptoms on self report questionnaire (Beck Depression Inventory – BDI-II

Measured before, mid, post and at 6 months follow-up.
Secondary outcome measure(s) 1. Anxiety related symptoms (Beck Anxiety Inventory - BAI)
2. Co-morbidity (SCID I)
3. Patients’ expectancies about treatment outcome
4. Meta-cognitive scales (Meta-cognitive Questionnaire - MCQ-30, negative and positive beliefs about rumination scales (NBRS PBRS), Rumination Response Scale (RRS)
5. CBT specific scales (Dysfunctional Attitude Scale DAS and Young’s Schema Inventory - short version)
6. Patient-therapist alliance (Havarth Aliance Inventory HAI)
7. Objective measure (Concentration and attention subtests from the WAIS)

Measured before, mid, post and at 6 months follow-up.
Sources of funding Investigator initiated and funded (UK)
Trial website http://www.cektos.dk/cektos/index.php?option=com_content&view=article&id=130&Itemid=157
Publications
Contact name Ms  Pia  Callesen
  Address Riddergade 7, 1
  City/town Næstved
  Zip/Postcode 4700
  Country Denmark
  Tel +4522684281
  Email Pia.callesen@cektos.dk
Sponsor University of Manchester (UK)
  Address c/o Adrian Wells, Ph.D
Professor of Clinical and Experimental Psychopathology
School of Psychological Sciences
Division of Clinical Psychology
Rawnsley Building
MRI
  City/town Manchester
  Zip/Postcode M13 9WL
  Country United Kingdom
  Email adrian.wells@manchester.ac.uk
  Sponsor website: http://www.manchester.ac.uk/
Date applied 09/02/2013
Last edited 04/03/2013
Date ISRCTN assigned 04/03/2013
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.